Publications by authors named "C J Kodde"
[Vaccinations in pulmonary diseases - part 2: herpes zoste, RSV, pneumococcal infection and pertussis].
Dtsch Med Wochenschr
November 2024
Article Synopsis
- RSV is a common respiratory virus that can seriously affect newborns, infants, and older adults; two new vaccines approved in 2023 provide strong protection without the need for annual boosters.
- The 20-valent pneumococcal vaccine (PCV20) is now recommended for those over 60 and younger individuals with risk factors, replacing the older 23-valent vaccine.
- Pertussis is often overlooked in adults, with recommendations for a booster alongside tetanus shots, especially for high-risk groups; shingles (Herpes Zoster) poses risks of severe complications, particularly for those with chronic lung diseases.
Article Synopsis
- The study examines the healthcare response to SARS-CoV-2 in Germany and Switzerland, highlighting disparities in treatment and surveillance that affected patient outcomes, particularly during ICU admissions and in-hospital mortality rates.
- Using data from over 1.4 million cases across 386 German and 41 Swiss hospitals from 2019 to 2022, the research shows that German patients were older, had more comorbidities, and faced higher rates of ICU admission (28% vs. 20%) and in-hospital mortality (21% vs. 12%) compared to Switzerland.
- The findings reveal significant healthcare discrepancies between the two countries, suggesting that varying treatment approaches and healthcare resources may have influenced the higher mortality
Article Synopsis
- The study investigates the rising issue of multidrug-resistant organisms (MDRO) and the gender-specific differences in their colonization and infection patterns.
- Data was collected from 86 hospitals in Germany between 2015 and 2020, revealing that males are at a higher risk for MDRO colonization and infection compared to females.
- The findings suggest the importance of considering gender in clinical practices related to MDRO susceptibility to improve patient care and outcomes.
[Vaccinations in pulmonary diseases - part 1: Covid and influenza].
Dtsch Med Wochenschr
August 2024
SARS-COV-2 : During the COVID-19 pandemic, mRNA-based vaccines were approved for the first time. The mRNA encodes for the viral spike protein, leading to the development of specific antibodies and T-cells, providing effective protection against severe illness and death from COVID-19. New variants regularly emerge due to rapid viral evolution.
View Article and Find Full Text PDFBackground: Even though several therapeutic options are available, COVID-19 is still lacking a specific treatment regimen. One potential option is dexamethasone, which has been established since the early beginnings of the pandemic. The aim of this study was to determine its effects on the microbiological findings in critically ill COVID-19 patients.
View Article and Find Full Text PDF